These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 33819752)

  • 21. T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.
    Omarini C; Piacentini F; Sperduti I; Cerma K; Barbolini M; Canino F; Nasso C; Isca C; Caggia F; Dominici M; Moscetti L
    BMC Cancer; 2022 Jun; 22(1):623. PubMed ID: 35672679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
    Reinhorn D; Kuchuk I; Shochat T; Nisenbaum B; Sulkes A; Hendler D; Rotem O; Tsoref D; Olitzky O; Goldvaser H; Sarfaty M; Neiman V; Prus J; Gottfried M; Yust-Katz S; Yerushalmi R
    Breast Cancer Res Treat; 2021 Jul; 188(2):379-387. PubMed ID: 33772709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence.
    Martin Huertas R; Fernández Abad M; Corral de la Fuente E; Serrano Domingo JJ; Martínez Jáñez N
    Clin Breast Cancer; 2021 Oct; 21(5):391-398. PubMed ID: 33549470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
    Migeotte A; Dufour V; van Maanen A; Berliere M; Canon JL; Taylor D; Duhoux FP
    BMC Cancer; 2021 Nov; 21(1):1204. PubMed ID: 34763656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
    Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
    Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
    Krop IE; Im SA; Barrios C; Bonnefoi H; Gralow J; Toi M; Ellis PA; Gianni L; Swain SM; Im YH; De Laurentiis M; Nowecki Z; Huang CS; Fehrenbacher L; Ito Y; Shah J; Boulet T; Liu H; Macharia H; Trask P; Song C; Winer EP; Harbeck N
    J Clin Oncol; 2022 Feb; 40(5):438-448. PubMed ID: 34890214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
    Okines AF
    Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How we treat patients with metastatic HER2-positive breast cancer.
    Nader-Marta G; Martins-Branco D; de Azambuja E
    ESMO Open; 2022 Feb; 7(1):100343. PubMed ID: 34995893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
    Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
    J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
    Perez EA; Hurvitz SA; Amler LC; Mundt KE; Ng V; Guardino E; Gianni L
    Breast Cancer Res; 2014 May; 16(3):R50. PubMed ID: 24887458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
    Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
    Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
    Paracha N; Reyes A; Diéras V; Krop I; Pivot X; Urruticoechea A
    Breast Cancer Res Treat; 2020 Apr; 180(3):597-609. PubMed ID: 32100144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
    Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
    Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
    Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
    Gamucci T; Pizzuti L; Natoli C; Mentuccia L; Sperduti I; Barba M; Sergi D; Iezzi L; Maugeri-Saccà M; Vaccaro A; Magnolfi E; Gelibter A; Barchiesi G; Magri V; D'Onofrio L; Cassano A; Rossi E; Botticelli A; Moscetti L; Omarini C; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Mazzotta M; Bria E; Foglietta J; Samaritani R; Garufi C; Mariani L; Barni S; Mirabelli R; Sarmiento R; Graziano V; Santini D; Marchetti P; Tonini G; Di Lauro L; Sanguineti G; Paoletti G; Tomao S; De Maria R; Veltri E; Paris I; Giotta F; Latorre A; Giordano A; Ciliberto G; Vici P
    Cancer Biol Ther; 2019; 20(2):192-200. PubMed ID: 30403909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.
    De Placido S; Giuliano M; Schettini F; Von Arx C; Buono G; Riccardi F; Cianniello D; Caputo R; Puglisi F; Bonotto M; Fabi A; Bilancia D; Ciccarese M; Lorusso V; Michelotti A; Bruzzese D; Veneziani BM; Locci M; De Laurentiis M; Arpino G
    Breast; 2018 Apr; 38():86-91. PubMed ID: 29287189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
    Williamson M; Press DJ; Hansen SA; Tomar A; Jhuti GS; Revil C; Gururaj K
    Breast Cancer; 2024 Jan; 31(1):84-95. PubMed ID: 37907759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
    de Haas SL; Slamon DJ; Martin M; Press MF; Lewis GD; Lambertini C; Prat A; Lopez-Valverde V; Boulet T; Hurvitz SA
    Breast Cancer Res; 2023 Jan; 25(1):2. PubMed ID: 36631725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice.
    Varghese D; Cruz GI; Johanson C; Toland L; Miranda M; Faherty EC; Harland D; Kaplan HG
    Int J Clin Oncol; 2024 Jun; 29(6):780-789. PubMed ID: 38528295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.